Search
Connect Biopharma Holdings Ltd
CNTBAdd to Watchlist
2.460USD
+0.070+2.93%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
154.27MMarket Cap
LossP/E TTM
More Details of Connect Biopharma Holdings Ltd Company
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Connect Biopharma Holdings Ltd Info
Ticker SymbolCNTB
Company nameConnect Biopharma Holdings Ltd
IPO dateMar 19, 2021
CEOQuart (Barry D)
Number of employees62
Security typeOrdinary Share
Fiscal year-endMar 19
Address3580 Carmel Mountain Road, Suite 200
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92130
Phone18587271040
Websitehttps://www.connectbiopharm.com
Ticker SymbolCNTB
IPO dateMar 19, 2021
CEOQuart (Barry D)
Company Executives of Connect Biopharma Holdings Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
82.82K
+3.40%
Ms. Lisa Peraza
Ms. Lisa Peraza
Vice President - Finance
Vice President - Finance
45.19K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
10.00K
--
Dr. Jean I. Liu, J.D.
Dr. Jean I. Liu, J.D.
Independent Director
Independent Director
5.06K
--
Dr. Kan Chen, Ph.D.
Dr. Kan Chen, Ph.D.
Independent Director
Independent Director
--
--
Mr. David L. Szekeres
Mr. David L. Szekeres
President
President
--
--
Mr. James Z. Huang
Mr. James Z. Huang
Independent Director
Independent Director
--
--
Mr. James A. (Jim) Schoeneck
Mr. James A. (Jim) Schoeneck
Director
Director
--
--
Kimberly Kimberly
Kimberly Kimberly
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
82.82K
+3.40%
Ms. Lisa Peraza
Ms. Lisa Peraza
Vice President - Finance
Vice President - Finance
45.19K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
10.00K
--
Dr. Jean I. Liu, J.D.
Dr. Jean I. Liu, J.D.
Independent Director
Independent Director
5.06K
--
Dr. Kan Chen, Ph.D.
Dr. Kan Chen, Ph.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Connect Biopharma Holdings Ltd?
The top five shareholders of Connect Biopharma Holdings Ltd are: Dr. Barry D. Quart, Pharm.D.
How many institutions hold shares of Connect Biopharma Holdings Ltd (CNTB)?
As of 2026Q1, 51 institutions hold shares of Connect Biopharma Holdings Ltd, with a combined market value of approximately 29.94M, accounting for 52.97% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 8109973.00.